Earnings Call · Q4 FY2022·2023-03-10

Q4 22EPS -52.94%·Rev n/aQ3 22EPS -90.00%·Rev n/aQ2 22EPS -100.00%*·Rev n/aQ1 22EPS 0.00%·Rev n/a⚠ consensus missing

ZEVRA THERAPEUTICS, INC. ZVRA

Nichol Ochsner — Vice President of Investor Relations and Corporate Communications

Richard Pascoe — Chief Executive Officer (CEO)

LaDuane Clifton — Chief Commercial Officer (CCO) or Head of Commercial

−19.4%1d on move date−17.9% vs SPY3d−20.6%5d−17.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ZVRA calls or request research access.

More ZVRA calls Browse calls Request research access